financetom
Business
financetom
/
Business
/
EU should limit curbs on outbound investment, semiconductor group says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EU should limit curbs on outbound investment, semiconductor group says
Aug 5, 2024 3:35 AM

AMSTERDAM (Reuters) - Semiconductor industry group SEMI Europe called on the European Union on Monday to place as few restrictions as possible on outbound investment in foreign computer chip technology by companies based in the bloc.

Proposals to screen outbound investment - European capital being invested in foreign semiconductor, AI and biotechnology companies - are being considered, though no EU decision is expected before 2025.

The U.S. has issued draft rules for banning some such investments in China that could threaten U.S. national security, part of a broader push to prevent U.S. know-how from helping the Chinese to develop sophisticated technology and dominate global markets.

"European semiconductor companies must be as free as possible in their investment decisions or otherwise risk losing their agility and relevance," SEMI Europe said in a paper outlining its recommendations.

It said policies under consideration by the EU appear to be overly broad and if adopted could force companies to disclose sensitive business information, adding that restrictions on cross-border research cooperation would be misplaced.

"We encourage the European Commission to further address these aspects and to not infringe on the ability of European multinational companies to carry out the necessary investments to sustain their operations," it said.

SEMI Europe represents about 300 Europe-based semiconductor firms and institutions, including companies such as ASML, ASM, Infineon, STMicroelectronics, NXP, and research centres such as imec, CEA-Leti and Fraunhofer.

Alongside the proposals for outbound investment screening, the EU has also been moving towards a law that screens inbound investments of foreign capital that might pose a security risk, such as purchases of European ports, nuclear plants and sensitive technologies.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stellantis Recalls Over 219,000 Vehicles in US Over Rear-View Camera Issue
Stellantis Recalls Over 219,000 Vehicles in US Over Rear-View Camera Issue
Sep 2, 2025
06:41 AM EDT, 09/02/2025 (MT Newswires) -- Stellantis' ( STLA ) Chrysler is recalling 219,577 Ram ProMaster and Dodge Journey vehicles in the US due to a rear-view camera defect that may reduce visibility behind the vehicle, the National Highway Traffic Safety Administration said Saturday. Dealers will replace the faulty cameras at no cost to owners, the auto safety regulator...
ECB on Track to Leave Rates on Hold Amidst French Political Uncertainty, Says Mitsubishi UFG; Comments on Euro
ECB on Track to Leave Rates on Hold Amidst French Political Uncertainty, Says Mitsubishi UFG; Comments on Euro
Sep 2, 2025
06:40 AM EDT, 09/02/2025 (MT Newswires) -- The euro (EUR) is continuing to trade close to recent highs against the US dollar (USD) at around the 1.1700 level, said MUFG. After a brief dip last week triggered in part by the pick-up in political uncertainty in France after Prime Minister Bayrou called a vote of confidence in his government to...
Radware Rolls Out New Cloud Application Security Centers in Israel, Columbia
Radware Rolls Out New Cloud Application Security Centers in Israel, Columbia
Sep 2, 2025
06:43 AM EDT, 09/02/2025 (MT Newswires) -- Radware ( RDWR ) said Tuesday it launched two new cloud security centers in Tel Aviv, Israel, and Bogota, Colombia. The Tel Aviv facility marks the company's second cloud security center in Israel, it said. ...
Upstream Bio Says Phase 2 Trial of Chronic Rhinosinusitis With Nasal Polyps Treatment Meets Primary Endpoint
Upstream Bio Says Phase 2 Trial of Chronic Rhinosinusitis With Nasal Polyps Treatment Meets Primary Endpoint
Sep 2, 2025
06:39 AM EDT, 09/02/2025 (MT Newswires) -- Upstream Bio ( UPB ) said Tuesday that a phase 2 trial of verekitug to treat chronic rhinosinusitis with nasal polyps met its primary endpoint and key secondary endpoints. Verekitug dosed 100 milligrams every 12 weeks showed statistically significant and clinically meaningful reductions in both endoscopic nasal polyp score and nasal congestion score...
Copyright 2023-2026 - www.financetom.com All Rights Reserved